ArticleJournal of cellular and molecular medicine2026
Casticin From Sanse Powder- In Vitro Release Medium Inhibits FAK/PI3K/AKT Phosphorylation Reducing Synovial Senescence and Alleviates Inflammation in Knee Osteoarthritis.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Casticin From Sanse Powder- In Vitro Release Medium Inhibits FAK/PI3K/AKT Phosphorylation Reducing Synovial Senescence and Alleviates Inflammation in Knee Osteoarthritis.Journal of cellular and molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Sanse Powder (SSP) has been shown to be effective in the clinical treatment of knee osteoarthritis (KOA), although its active components and underlying mechanisms remain unclear. In this study, we collected the in vitro release medium of SSP (SSP-IVRM) using an in vitro release test and evaluated its pharmacological effects in a KOA rat model. Ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) was used to identify active constituents in SSP-IVRM, while network pharmacology and molecular docking were applied to screen key compounds and molecular targets. In vivo and in vitro experiments using histological staining and molecular biology techniques were performed to investigate the effects of casticin (CAS), a major component of SSP-IVRM, on KOA-related synovitis. UHPLC-MS/MS identified CAS, monocerin, and chlorogenic acid as major components. Network pharmacology and molecular docking associated these compounds with PI3K signalling and cellular senescence. CAS significantly improved synovial pathology, reduced pro-inflammatory cytokines and chemokines, modulated fibrosis- and senescence-related genes and proteins, and decreased synovial fibroblast senescence. Transcriptomic analysis further implicated cell adhesion and the PI3K-AKT pathway. Additional experiments demonstrated that CAS alleviates KOA-related inflammation and cellular senescence by inhibiting FAK/PI3K/AKT phosphorylation. These findings indicate that CAS in SSP-IVRM reduces synovial fibroblast senescence and inflammation through inhibition of the FAK/PI3K/AKT signalling pathway, thereby exerting therapeutic effects against KOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.